Long-term mortality and recurrent vascular events in lacunar versus non-lacunar ischaemic stroke: A cohort study

Suzanne Portegijs¹,²,*, Ariel Y Ong³,*, Nynke Halbesma¹, Aidan Hutchison¹,⁴, Cathie LM Sudlow¹,⁴ and Caroline A Jackson¹

Abstract

Introduction: Studies of differences in very long-term outcomes between people with lacunar/small vessel disease (SVD) versus other types of ischaemic stroke report mixed findings, with limited data on myocardial infarction (MI). We investigated whether long-term mortality, recurrent stroke and MI risks differ in people with versus without lacunar/SVD ischaemic stroke.

Patients and methods: We included first-ever strokes from a hospital-based stroke cohort study recruited in 2002–2005. We compared risks of death, recurrent stroke and MI during follow-up among lacunar/SVD versus other ischaemic stroke subtypes using Cox regression, adjusting for confounding factors.

Results: We included 812 participants, 283 with lacunar/SVD ischaemic stroke and 529 with other stroke. During a median of 9.2 years (interquartile range 3.1–11.8), there were 519 deaths, 181 recurrent strokes and 79 MIs. Lacunar/SVD stroke was associated with lower mortality (adjusted HR 0.79, 95% CI 0.65 to 0.95), largely due to markedly lower all-cause mortality in the first year. From one year onwards this difference attenuated, with all-cause mortality only slightly and not statistically significantly lower in the lacunar/SVD group (0.86, 95% CI 0.70 to 1.05). There was no clear difference in risk of recurrent stroke (HR 0.84, 95% CI 0.61–1.15) or MI (HR 0.83, 95% CI 0.52–1.34).

Conclusion: Long-term risks of all-cause mortality, recurrent stroke and MI are similar, or only slightly lower, in patients with lacunar/SVD as compared to other ischaemic stroke. Patients and physicians should be as vigilant in optimising short- and long-term secondary prevention of vascular events in lacunar/SVD as for other stroke types.

Keywords
Ischaemic stroke, lacunar stroke, small vessel disease, mortality, recurrent stroke, myocardial infarction

Date received: 26 February 2021; accepted: 4 November 2021

Introduction

In high-income settings, ischaemic strokes comprise about 85% of all strokes, around 25% of which are ‘lacunar’ strokes, attributed to small vessel disease (SVD) affecting the deep penetrating arterioles of the brain. Until relatively recently, compared with other stroke subtypes, lacunar/SVD strokes were considered to be relatively benign, due to lower stroke severity at initial presentation and lower early case fatality. However, lacunar/SVD strokes are now recognised to have substantial long-term consequences, including physical and cognitive decline.

In a previous systematic review and meta-analysis, we found lower risks of death and recurrent stroke in the first month after lacunar/SVD versus other ischaemic stroke subtypes, with attenuation of these differences thereafter.
However, very few studies reported on long-term outcomes, comparisons of recurrent stroke risk beyond one month were limited by low precision and risk of myocardial infarction (MI) among ischaemic stroke subtypes had rarely been investigated. Our own hospital-based stroke cohort study, with follow-up for up to four years, subsequently reported a lower early risk of recurrent stroke among people with lacunar/SVD versus other ischaemic stroke subtypes, and a trend towards a reduced risk of MI among those with lacunar/SVD stroke (but based on small numbers of MI). Over the last decade, more studies have reported on outcomes among different ischaemic stroke subtype groups over a longer follow-up period (exceeding five years), but findings appear somewhat mixed and data on risks of MI remain scarce.

Differences in long-term prognosis for vascular events following different subtypes of ischaemic stroke may have important implications for clinical management, particularly vascular secondary prevention. In the present study, we extended the follow-up of our hospital-based stroke cohort for up to 14 years through individual-level linkages to Scotland’s national hospital admission and mortality databases, to compare long-term risks of death, recurrent stroke and MI among people with lacunar/SVD versus other ischaemic stroke subtypes.

**Patients and methods**

This article is presented in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. The study was approved by the relevant regional Research Ethics Committee (LREC 2001/4/46), and the Scottish National Health Service (NHS) Public Benefit and Privacy Panel provided approval for data linkage.

**Setting and study population**

We included participants recruited to the Edinburgh Stroke Study (ESS), a prospective cohort of consecutive consenting adult patients with ischaemic or haemorrhagic stroke (defined according to the classical WHO criteria), admitted as inpatients or referred by primary care physicians to the stroke/transient ischaemic attack outpatient clinic at a large university hospital from 2002–2005. At recruitment, we collected information on stroke onset, symptoms and signs, clinical risk factors, premorbid functional status, lifestyle factors and results of clinical investigations. We obtained informed consent, including for long-term follow-up through linkage to national health records, from all recruited patients, or from relatives (or where necessary through waiver of consent) when patients were unable to provide consent.

For the present study, we linked our original cohort to all Scottish general hospital inpatient records and national death records and included patients with a first-ever ischaemic stroke aged 40 years or more at recruitment.

**Ischaemic stroke subtype classification**

We categorised ischaemic stroke subtypes according to an anatomical classification based on clinical and brain imaging features. We used the Oxfordshire Community Stroke Project (OCSP) classification to assign a clinical syndrome indicating the presumed site and size of the causative infarct using the clinical features of the stroke which was then modified if necessary by the findings on brain imaging if an infarct considered relevant to the presenting stroke was present (Figure 1; Supplementary Table 1).

To allow comparisons with studies that used a mechanistic ischaemic stroke classification, we retrospectively applied a modified Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification to create ischaemic stroke subtype groups based on presumed stroke mechanism (Supplementary Table 1). In secondary analyses, we compared SVD versus large vessel disease (LVD) or cardioembolic (CE) stroke.

**Follow-up and outcome definitions**

During the original study, we used a ‘hot pursuit’ method to prospectively follow patients for one to four years post-stroke for death, recurrent stroke and MI. These methods included multiple overlapping sources, including alerts from clinical colleagues, patient questionnaires, contact with general practitioners and death certificates. Whenever possible, we arranged for specialist review and investigation of patients with a suspected recurrent stroke. For patients with suspected MI, and those unable to attend a clinical assessment for suspected recurrent stroke, we confirmed or refuted events through review of paper and electronic medical records. In the present study, we ascertained recurrent stroke during the first year post-stroke solely from the prospective hot pursuit methods (defining recurrent stroke using the same WHO definition as for index stroke and requiring a period of neurological stability of 24 hours between index and recurrent stroke, and exclusion of other potential causes of neurological deterioration). Relying on linkages to coded hospital admission data to identify recurrences during this period, when recurrence risk is highest, would have underestimated early recurrence risk. From one-year post-stroke onwards, we identified recurrent strokes from linkage, via a unique community health index number, to hospital admission and mortality records. To optimise the accurate identification of clinically symptomatic strokes fulfilling the WHO definition and occurring beyond one-year of the index stroke, we used stroke-specific ICD-10 codes (i.e. I60, I61, I63 and I64), appearing in the primary or secondary hospital diagnosis or cause of death data fields.
We ascertained MI events during the whole period from hospital admission or mortality records which indicated an acute MI (ICD-10 I21) in the primary or secondary position and from the ‘hot pursuit’ prospective follow-up phase of the ESS (where MI was defined as either autopsy evidence or at least two of the following: symptoms of myocardial ischaemia [e.g. chest pain]; enzyme changes indicative of MI [generally an acute rise in troponin level]; and ECG changes suggesting new ischaemia [new ST-T wave changes, Q waves or left bundle branch block] or sudden death without evidence of an alternative cause).

We identified all-cause mortality through linkage to coded, national mortality records.

**Statistical analysis**

We performed statistical analyses using SPSS version 22 (IBM, New York, USA) and Stata version 14. We compared baseline characteristics using the χ² test for categorical variables, Student’s t-test for continuous variables and tests for differences for non-normally distributed variables. For each outcome, we used Kaplan–Meier survival analysis to obtain 1-year, 5-year and 10-year cumulative incidence with 95% confidence intervals (CIs) for lacunar/SVD and other ischaemic subtype groups. We compared people with lacunar/SVD versus other ischaemic strokes, using Cox regression analysis to obtain age- and sex- adjusted and additionally adjusted hazard ratios (HRs) with 95% CIs for each outcome, for the entire follow-up time, 0–1 year and one year to end of follow-up. In the models for mortality and recurrent stroke, we adjusted for age, sex, history of ischaemic heart disease, atrial fibrillation, cardiac failure and smoking status. In the analysis of MI, we adjusted for age, sex, history of ischaemic heart disease, atrial fibrillation and smoking. We followed patients from stroke date to date of outcome, death or end of follow-up (31 December 2015). Information on one or more covariates was missing in only 12 patients and so we performed a complete-case analysis. We checked models for violation of the proportional hazard assumption using log minus log plots and plotting the Schoenfeld residuals.

We performed sensitivity analyses where we calculated sub-distribution HRs for recurrent stroke and MI (treating death as a competing risk). Since stroke severity was not documented for the majority of patients, we repeated the analyses for each outcome stratifying by inpatient/outpatient status at recruitment, as a proxy for more versus less severe strokes. We also performed a sensitivity analysis excluding patients who died within the first three months of the stroke event.

**Results**

We included 812 patients with first-ever ischaemic stroke (283 lacunar/SVD, 529 other ischaemic; Figure 1), followed
up for a maximum of 14 years (median 9.2, IQR 3.1–11.8).

Of these 812 patients, 509 had a visible relevant infarct on their scan, 64 (13%) of whom were allocated to a different comparison group (i.e. lacunar/SVD or other ischaemic stroke type) than would have been the case based on their clinical syndrome alone, with lacunar and non-lacunar strokes equally misclassified. Applying this to the number with no visible infarct, we estimate that 6% of participants were residually misclassified between comparison groups. The inclusion of a slightly higher proportion of lacunar patients (35%) than might be expected reflects the inclusion of (i) milder strokes recruited from an outpatient clinic servicing the whole city and (ii) inpatients from one of three city hospitals receiving acute stroke patients. Patients with lacunar/SVD stroke were slightly (but not significantly) younger than patients with other ischaemic stroke subtypes and more often male and current smokers. Atrial fibrillation, severe ipsilateral carotid stenosis and previous history of ischaemic heart disease were significantly less common in patients with lacunar/SVD versus other ischaemic stroke (Table 1).

During follow-up, 159 and 360 deaths occurred among patients with lacunar/SVD and other ischaemic stroke, respectively. During the first year, cumulative mortality was lower among people with lacunar/SVD than other ischaemic stroke. This difference persisted at 5 years and 10 years, but attenuated between 5 and 10 years (Figure 2(a) and Table 2). In adjusted analyses, people with lacunar/SVD stroke had lower mortality risk than other ischaemic stroke subtypes over the entire follow-up period (adjusted HR lacunar/SVD vs others: 0.79, 95% CI 0.65 to 0.95; p = 0.015), largely explained by a much lower risk of dying after lacunar/SVD stroke in the first year (0–1 year HR 0.49, 95% CI 0.28 to 0.84). From one year onwards, the difference in risk attenuated, suggesting only a slightly lower mortality risk among the lacunar/SVD group, although this did not reach statistical significance (0.86, 95% CI 0.70 to 1.05; Table 3).

When we excluded patients who died within three months of the stroke, we found that, among 766 remaining patients, those with a lacunar/SVD stroke had an 18% lower mortality risk than other ischaemic stroke (adjusted HR 0.82, 95% CI 0.67 to 1.00, p = 0.045).

During the entire follow-up period, 59 and 122 recurrent strokes occurred among patients with lacunar/SVD and other ischaemic stroke, respectively. At 1, 5 and 10 years, there was little difference in the cumulative incidence of recurrent stroke (Figure 2(d) and Table 2). In age- and sex-adjusted and fully adjusted analyses, there was no statistically significant difference in the risk of recurrence between lacunar/SVD versus other ischaemic stroke.

---

Table 1. Baseline characteristics of patients with lacunar/SVD and other ischaemic stroke subtypes.

| Characteristic                        | Lacunar/SVD stroke (N = 283) n (%) | Other ischaemic stroke subtypes (N = 529) n (%) | P-value‡ |
|---------------------------------------|------------------------------------|------------------------------------------------|----------|
| Age at stroke (mean years ± SD)       | 68.7 (11.9)                        | 72.5 (11.7)                                    | 0.46     |
| Male                                  | 170 (60.1)                         | 252 (47.6)                                     | 0.001    |
| Prior TIA                             | 49 (17.3)                          | 96 (18.2)                                      | 0.76     |
| Hypertension†                         | 134 (47.3)                         | 277 (52.4)                                     | 0.13     |
| Diabetes mellitus‡                    | 36 (12.7)                          | 55 (10.4)                                      | 0.32     |
| Prior IHD§                            | 57 (20.1)                          | 144 (27.2)                                     | 0.03     |
| Cardiac failure¶                      | 10 (3.5)                           | 35 (6.6)                                       | 0.07     |
| Atrial fibrillation**                 | 27 (9.6)                           | 107 (20.2)                                     | <0.001   |
| Ipsilateral carotid stenosis†‡        | 15 (5.3)                           | 95 (18.0)                                      | <0.001   |
| Smoking                               | 108 (38.4)                         | 153 (29.3)                                     | 0.008    |
| Alcohol units/week, median (IQR)      | 4 (0-15)                           | 1 (0-10)                                       | 0.2      |
| Independent in ADL before stroke      | 276 (97.5)                         | 499 (94.5)                                     | 0.05     |
| On antiplatelet or anticoagulant at onset | 107 (37.8)                     | 237 (44.8)                                     | 0.06     |
| CT performed                          | 221 (78.1)                         | 443 (83.7)                                     | 0.04     |
| MRI performed                         | 73 (25.8)                          | 116 (21.9)                                     | 0.21     |

‡P-value for statistical test of difference between SVD/lacunar versus other ischaemic stroke.
†Treated hypertension in medical history.
‡Diagnosis of or using medication for diabetes mellitus.
§MI, angina or coronary revascularisation in medical history.
¶Clinical signs of heart failure or taking at least two drugs for its treatment.
††70% internal carotid artery stenosis (missing in 11 patients with Lacunar/SVD stroke and 43 patients with other ischaemic stroke subtypes).
†‡Taking any antiplatelet or warfarin at onset of stroke.
ADL - activities of daily living; CT - computed tomography; IHD - ischaemic heart disease; IQR - interquartile range; MRI - magnetic resonance imaging; OCSP - Oxfordshire Community Stroke Project Subtype Classification; TIA - transient ischaemic attack.
subtypes over the entire follow-up period (fully adjusted HR: 0.84, 95% CI 0.61 to 1.15), or when restricting the time period to 0–1 year and to one-year onwards (Table 3).

There were 79 MI events (27 and 52 among those with lacunar/SVD and other ischaemic stroke, respectively), with the cumulative incidence of MI similar in both groups at 1, 5 and 10 years (Figure 2(c) and Table 2). In age- and sex-adjusted analyses, there was no statistically significant difference in risk of MI between lacunar/SVD versus other ischaemic stroke (HR 1.0, 95% CI 0.62 to 1.65; Table 3). Similar results were obtained when adjusting for additional confounders and when examining the 0–1 year and 1-year onwards time-periods (Table 3).

We observed similar associations for recurrent stroke and MI risk when we accounted for the competing risk of death. When stratifying by inpatient/outpatient status, results were similar among inpatients as in our primary analysis, but there were no differences in death or recurrent stroke among

---

**Table 2.** Cumulative incidence of mortality, recurrent stroke and myocardial infarction at 1, 5 and 10 years, in patients with lacunar/SVD and other (non-lacunar/non-SVD) ischaemic stroke subtypes.

| Outcome          | Lacunar/SVD (N = 283) | Cumulative incidence (95% CI) | Other ischaemic stroke subtypes (N = 529) | Cumulative incidence (95% CI) |
|------------------|------------------------|-------------------------------|------------------------------------------|-------------------------------|
| **Mortality**    |                        |                               |                                          |                               |
| 1 year           | 16                     | 5.7 (3.5–9.1)                 | 83                                       | 15.7 (12.9–19.1)              |
| 5 years          | 63                     | 22.3 (17.9–27.6)              | 205                                      | 38.8 (34.8–43.1)              |
| 10 years         | 128                    | 45.2 (39.7–51.2)              | 309                                      | 58.4 (54.3–62.6)              |
| **Recurrent stroke** |                      |                               |                                          |                               |
| 1 year           | 21                     | 7.6 (5.0–11.4)                | 49                                       | 9.9 (12.9–7.6)                |
| 5 years          | 43                     | 16.3 (12.4–21.4)              | 91                                       | 20.1 (16.7–24.2)              |
| 10 years         | 55                     | 22.3 (17.5–28.1)              | 118                                      | 29.2 (24.9–34.2)              |
| **Myocardial infarction** |                    |                               |                                          |                               |
| 1 year           | 6                      | 2.2 (1.0–4.8)                 | 16                                       | 3.3 (2.0–5.3)                 |
| 5 years          | 13                     | 5.0 (2.9–8.5)                 | 40                                       | 9.3 (6.9–12.5)                |
| 10 years         | 25                     | 11.1 (7.6–16.1)               | 47                                       | 11.9 (8.9–15.6)               |

CI - confidence interval; SVD - small vessel disease.
Table 3. Hazard ratios from Cox proportional hazard regression analyses for all-cause mortality, recurrent stroke and myocardial infarction, comparing lacunar/SVD versus other (non-lacunar/non-SVD) ischaemic stroke subtypes, by follow-up time period.

| Outcome                  | Entire follow-up perioda | 0–1 year HR (95% CI) | 1 year onwards HR (95% CI) |
|--------------------------|--------------------------|----------------------|---------------------------|
| Mortality                | n = 508                  | n = 95               | n = 413                   |
| Age- and sex- adjusted   | 0.75 (0.62–0.91)†        | 0.43 (0.25–0.74)††   | 0.83 (0.67–1.01)‡‡         |
| “Fully adjusted”§         | 0.79 (0.65–0.95)§        | 0.49 (0.28–0.84)††   | 0.86 (0.70–1.05)§§         |
| Recurrent stroke         | n = 180                  | n = 69               | n = 111                   |
| Age- and sex- adjusted   | 0.80 (0.59–1.10)††       | 0.79 (0.47–1.33)††   | 0.81 (0.55–1.20)††         |
| “Fully adjusted”          | 0.84 (0.61–1.15)††       | 0.82 (0.48–1.40)††   | 0.84 (0.57–1.25)††         |
| Myocardial infarction    | n = 79                   | n = 22               | n = 57                    |
| Age- and sex- adjusted   | 0.82 (0.51–1.31)††       | 0.74 (0.29–1.92)††   | 0.91 (0.53–1.56)††         |
| “Fully adjusted”‡‡       | 0.83 (0.52–1.34)††       | NC                   | 0.93 (0.54–1.60)††         |

*800 people with complete information on all covariates included in analyses for the entire time period.
†p-value 0.002
‡p-value 0.06.
§In addition to age and sex, also adjusted for history of ischaemic heart disease, atrial fibrillation, history of cardiac failure and smoking status (all of which were associated with type of stroke and had none or almost no missing values); inclusion of independence in activities of daily living (ADL) did not contribute to the fit of the model and so was not included in the final fully adjusted model.
¶p-value 0.02.
‖p-value 0.01.
††p-value >0.05.
‡‡Adjusted for age, sex, history of ischaemic heart disease, atrial fibrillation and smoking (not adjusted for history of cardiac failure due to smaller number of outcome events).
CI - confidence interval; HR - hazard ratio; n - number of deaths, recurrent strokes or myocardial infarction events occurring during each time period; NC - not calculated (too few myocardial infarctions within the first year to adjust for additional covariates); SVD - small vessel disease

lacunar/SVD versus other ischaemic stroke patients assessed as outpatients (Supplementary Tables 2 and 3).

In secondary analyses using the mechanistic (TOAST-based) classification, 224 ischaemic strokes were classified as SVD, 82 as LVD and 141 as CE. A large proportion of ischaemic strokes (53.7%) had no determined mechanistic subtype due to having either more than one potential aetiology or undetermined aetiology, and so were excluded (Supplementary Table 4). We obtained similar results to the primary analyses when comparing cumulative incidence of mortality, recurrent stroke and MI at one, five and 10 years among SVD versus non-SVD ischaemic subtypes, although differences were generally more marked between SVD and CE than SVD and LVD stroke. Results of survival analyses were broadly similar to those from primary analyses for each outcome (Supplementary Tables 5 and 6).

Discussion

During 14 years of follow-up, our study found that, in the long-term, all-cause mortality was only slightly lower in patients with lacunar/SVD stroke compared to other ischaemic stroke subtypes. There was no clear difference in the long-term risk of recurrent stroke or MI, although relatively wide estimates did not preclude lower risks in people with lacunar/SVD strokes.

Our findings on long-term mortality generally align with a number of previous studies with five or more years of follow-up, which found similar or only slightly lower mortality rates between lacunar/SVD versus other ischaemic stroke comparison groups.8,10,12,16–23 In contrast to this, one study reported a marked increased mortality risk in people with lacunar/SVD stroke, as compared to other ischaemic stroke,11 but this may be due to the inclusion of a selected population with very high rates of prior cardiac comorbidities. We found no significant difference in the very long-term risk of recurrent stroke, although relatively wide CIs did not exclude the possibility of a slightly lower risk in the lacunar/SVD group. This is largely in keeping with other studies, including contemporaneous studies,12,16,22,24, which similarly found no difference in long-term risk of recurrent stroke risk among people with lacunar/SVD versus other ischaemic stroke. Findings on MI risk across the small number of existing studies that have reported on this are inconsistent. Among just four studies reporting on a total of 270 MI or acute coronary events, two found no difference10,25, and two found a lower risk of MI in those with lacunar/SVD stroke.12,24 This may have been due to: small numbers of MI events in some studies10,25; differences in the composition of the non-lacunar/SVD comparison group; and inclusion of all acute coronary events in some studies.

Our study has various strengths. We included a prospectively recruited cohort of stroke patients which comprised both inpatients and outpatients, resulting in a study population which, in this particular setting, is more representative of the general stroke population than studies based
on hospital admitted strokes only. Patients were carefully phenotyped in terms of ischaemic stroke subtype classification using the OCSP classification, which has high inter-rater reliability, is predictive of clinical outcomes and is widely used in clinical trials and epidemiological studies. Recurrent strokes occurring within the first year of stroke are particularly well captured, given our multiple hot pursuit methods and use of advanced brain imaging where possible. The capacity for health record linkage in Scotland facilitated long-term follow-up, resulting in one of the largest long-term follow-up studies of ischaemic stroke subtypes, including for the occurrence of MI which has previously rarely been reported.

Our study does have limitations. Although widely used in clinical trials and epidemiological studies, the OCSP classification does have the potential for misclassification of stroke ischaemic stroke subtypes. Assignment of OCSP based on clinical symptoms alone results in approximately 20 percent of lacunar strokes being misclassified as cortical stroke and vice versa. However, we sought to mitigate this potential for misclassification by using a clinical and imaging-based approach, thus reducing this misclassification. Unfortunately our study was not resourced to perform MRI on all index strokes and so some residual misclassification of ischaemic stroke subtypes is likely. The alternative mechanistic classification method available at the time of patient recruitment was the TOAST classification, which was limited by concerns around the definition of lacunar stroke and the large proportion of patients with multiple or no determined causes. Whilst new aetiological ischaemic stroke classifications have been developed since, these remain hampered by important limitations, including reliability, validity and ease of application in a clinical setting. Our study will not have captured recurrent strokes assessed in outpatients beyond the first year of follow-up. Since people with lacunar/SVD strokes may be more likely to have a lacunar/SVD recurrence and lacunar/SVD strokes are more likely than other stroke subtypes to be assessed in an outpatient setting, we may have underestimated the longer term risk of recurrent stroke, particularly in lacunar/SVD stroke patients. Using routinely collected data may also introduce the possibility of diagnostic or recording errors. Unfortunately we were unable to adjust for stroke severity. However, it is interesting that analysis by inpatient/outpatient assessment status (used as a proxy for severity) found similar findings for inpatients but not outpatients. The requirement for consent meant that not all eligible patients were included. However, as shown previously, we recruited 88% of eligible patients and found no difference in age, sex and stroke subtype distribution between participants and non-participants. We did find that participants were more likely to be admitted to a stroke unit and were more affluent. Finally, some loss to follow-up may have occurred through migration out of Scotland, but this will be minimal given the age of our cohort and migration occurring mainly among younger people.

The results of our study emphasise the need for clinicians, patients and carers to recognise the non-benign nature of lacunar/SVD stroke, despite symptoms being milder than other types of ischaemic stroke and the importance of adhering to secondary prevention medication. These findings complement the evidence from randomised controlled trials which demonstrates that the relative effect of statins and blood pressure lowering and antiplatelet medications over the long-term does not differ between ischaemic stroke subtypes. Our findings that lacunar ischaemic stroke patients have a similar prognosis for relevant outcomes as other ischaemic stroke patients, and therefore as much to gain through long-term preventive efforts, help to emphasise the importance of such preventive efforts in all ischaemic stroke patients, as per clinical guidelines. Under ideal circumstances, secondary stroke prevention treatment is thought to reduce risk of recurrent stroke by about 80%. However, secondary prevention has been shown to be sub-optimal, through failure to successfully translate evidence-based recommendations into clinical practice, particularly in low-income countries. Non-adherence to prescribed secondary prevention medication increases with time from stroke and is associated with low perceived benefit of medication and younger age.

Further research, including pooling of relevant studies to improve study power and harmonise key definitions, is needed to conclusively establish whether MI risk differs between lacunar/SVD versus other ischaemic stroke subtypes. We should also identify reasons for sub-optimal implementation of clinical guidelines on secondary prevention and determine whether adherence differs between those with lacunar versus other stroke subtypes.

**Conclusion**

In the long-term, patients with lacunar/SVD stroke may have only a slightly lower risk of death compared to patients with other ischaemic strokes. There is no conclusive evidence that recurrent stroke and MI risks differ between these groups. Patients and physicians should be as vigilant in optimising short and long-term secondary prevention of vascular events among patients following lacunar/SVD stroke as for other types of ischaemic stroke.

**Acknowledgments**

We thank Caroline Cristofaro, Laurie Guillot L and Jacki Liu for their assistance with systematically reviewing the literature.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The Edinburgh Stroke Study was funded by the Wellcome Trust (Clinician Scientist award 063668/Z/01/A to CLMS). The linkage to routine hospital admission and mortality data was funded by Chancellor Fellowship start-up funds awarded to CAJ. Requests to access the data used in this study should be directed to the principal investigator of the Edinburgh Stroke Study, Prof Cathie Sudlow.

Contributorship
CLMS conceived the Edinburgh Stroke Study and gained ethical approval. CLMS and CAJ coordinated patient recruitment and data collection. All authors contributed to the data analysis protocol, SP and AYO conducted the analyses and all authors contributed to interpretation of the results. SP and AYO wrote the first draft of the manuscript. All authors reviewed and edited the manuscript and approved the final version of the manuscript.

Ethical approval
The study was approved by the relevant regional Research Ethics Committee (LREC 2001/4/46), and the Scottish National Health Service (NHIS) Public Benefit and Privacy Panel provided approval for data linkage.

Informed consent
We obtained informed consent, including for long-term follow-up through linkage to national health records, from all recruited patients, or from relatives (or where necessary through waiver of consent) when patients were unable to provide consent.

Guarantor
CAJ

ORCID iD
CA Jackson https://orcid.org/0000-0002-2067-2811

Supplementary material
Supplementary material for this article is available online.

References
1. Krishnamurthi RV, Feigin VL, Forouzanfar MH, et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. The Lancet Global Health 2013; 1: e259–e281. DOI: 10.1016/S2214-109X(13)70089-5.
2. Ornello R, Degan D, Tiseo C, et al. Distribution and Temporal Trends From 1993 to 2015 of Ischemic Stroke Subtypes. Stroke 2018; 49: 814–819. DOI: 10.1161/STROKEAHA.117.020031.
3. Behrouz R, Malek AR and Torbey MT. Small vessel cerebrovascular disease: the past, present, and future. Stroke Research and Treatment 2012; 2012: 1–8. DOI: 10.1155/2012/839151.
4. Norving B. Long-term prognosis after lacunar infarction. The Lancet Neurology 2003; 2: 238–245. DOI: 10.1016/s1474-4422(03)00352-1.
5. Makin SDJ, Turpin S, Dennis MS and Wardlaw JM. Cognitive impairment after lacunar stroke: systematic review and meta-analysis of incidence, prevalence and comparison with other stroke subtypes. Journal of Neurology, Neurosurgery & Psychiatry 2013; 84: 893–900. DOI: 10.1136/jnnp-2012-303645.
6. Jackson C and Sudlow C. Comparing risks of death and recurrent vascular events between lacunar and non-lacunar infarction. Brain 2005; 128: 2507–2517. DOI: 10.1093/brain/awh636.
7. Jackson CA, Hutchison A, Dennis MS, et al. Differences Between Ischemic Stroke Subtypes in Vascular Outcomes Support a Distinct Lacunar Ischemic Stroke Arteriopathy. Stroke 2009; 40: 3679–3684. DOI: 10.1161/STROKEAHA.109.558221.
8. Eriksson S-E and Olsson J-E. Survival and recurrent strokes in patients with different subtypes of stroke: a fourteen-year follow-up study. Cerebrovascular Diseases 2001; 12: 171–180. DOI: 10.1159/000047700.
9. Jones SB, Sen S, Lakshminarayan K, et al. Poststroke outcomes vary by pathogenic stroke subtype in the Atherosclerosis Risk in Communities Study. Stroke 2013; 44: 2307–2310. DOI: 10.1161/STROKEAHA.113.008380.
10. Lv Y, Fang X, Asmaro K, et al. Five-year prognosis after mild to moderate ischemic stroke by stroke subtype: a multi-clinic registry study. PloS One 2013; 8: e75019. DOI: 10.1371/journal.pone.0075019.
11. Melkas S, Putaala J, Oksala NKJ, et al. Small-vessel disease relates to poor poststroke survival in a 12-year follow-up. Neurology 2011; 76: 734–739. DOI: 10.1212/WNL.0b013e31820db666.
12. Ntaios G, Pavavasileiou V, Makaritsis K, et al. Association of ischaemic stroke subtype with long-term cardiovascular events. European Journal of Neurology 2014; 21: 1108–1114. DOI: 10.1111/ene.12438.
13. Aho K, Harmsen P, Hatano S, et al. Cerebrovascular disease in the community: results of a WHO collaborative study. Bulletin of the World Health Organization 1980; 58: 113–30.
14. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35–41. DOI: 10.1161/01.STR.24.1.35.
15. Woodfield R, Grant I, Sudlow CLM, et al. Accuracy of electronic health record data for identifying stroke cases in large-scale epidemiological studies: a systematic review from the UK biobank stroke outcomes group. PloS One 2015; 10: e0140533. DOI: 10.1371/journal.pone.0140533.
16. Cabral NL, Nagel V, Conforto AB, et al. High five-year mortality rates of ischemic stroke subtypes: A prospective cohort study in Brazil. International Journal of Stroke 2019; 14: 491–499. DOI: 10.1177/1747493018806197.
17. Dejong G, Vanraak L, Kessels F, et al. Stroke subtype and mortality follow-up study in 998 patients with a first cerebral infarct. *Journal of Clinical Epidemiology* 2003; 56: 262–268. DOI: 10.1016/s0895-4356(02)00572-3.

18. Kaplan RC, Tirschwell DL, Longstreth WT, et al. Vascular events, mortality, and preventive therapy following ischemic stroke in the elderly. *Neurology* 2005; 65: 835–842. DOI: 10.1212/01.wnl.0000176058.09848.bb.

19. Sacco S, Marini C, Totaro R, et al. A population-based study of the incidence and prognosis of lacunar stroke. *Neurology* 2006; 66: 1335–1338. DOI: 10.1212/01.wnl.0000210457.89798.0e.

20. Saber H, Thrift AG, Kapral MK, et al. Incidence, recurrence, and long-term survival of ischemic stroke subtypes: A population-based study in the Middle East. *International Journal of Stroke* 2017; 12: 835–843. DOI: 10.1177/1747493016684843.

21. Saber H, Thrift AG, Kapral MK, et al. Incidence, recurrence, and long-term survival of ischemic stroke subtypes: A population-based study in the Middle East. *International Journal of Stroke* 2017; 12: 835–843. DOI: 10.1177/1747493016684843.

22. Bjerkreim AT, Khanevski AN, Thomassen L, et al. Five-year readmission and mortality differ by ischemic stroke subtype. *Journal of the Neurological Sciences* 2019; 403: 31–37. DOI: 10.1016/j.jns.2019.06.007.

23. Fang X-H, Wang W-H, Zhang X-Q, et al. Incidence and survival of symptomatic lacunar infarction in a Beijing population: a 6-year prospective study. *European Journal of Neurology* 2012; 19: 1114–1120. DOI: 10.1111/j.1468-1331.2012.03709.x.

24. Li L, Yin GS, Geraghty OC, et al. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. *The Lancet Neurology* 2015; 14: 903–913. DOI: 10.1016/S1474-4422(15)00132-5.

25. Rincon F, Dhamoon M, Moon Y, et al. Stroke location and association with fatal cardiac outcomes. *Stroke* 2008; 39: 2425–2431. DOI: 10.1161/STROKEAHA.107.506055.

26. Bamford J, Sandercock P, Dennis M, et al. Classification and natural history of clinically identifiable subtypes of cerebral infarction. *The Lancet* 1991; 337: 1521–1526. DOI: 10.1016/0140-6736(91)93206-o.

27. Pittock SJ, Meldrum D, Hardiman O, et al. The Oxfordshire Community Stroke Project classification: correlation with imaging, associated complications, and prediction of outcome in acute ischemic stroke. *Journal of Stroke and Cerebrovascular Diseases* 2003; 12: 1–7. DOI: 10.1053/jscd.2003.7.

28. Giacomozzi S, Caso V, Agnelli G, et al. Lacunar stroke syndromes as predictors of lacunar and non-lacunar infarcts on neuroimaging: a hospital-based study. *Internal and Emergency Medicine* 2020; 15: 429–436. DOI: 10.1007/s11739-019-02193-2.

29. Potter G, Doubl F, Jackson C, et al. Associations of clinical stroke misclassification (‘clinical-imaging dissociation’) in acute ischemic stroke. *Cerebrovascular Diseases* 2010; 29: 395–402. DOI: 10.1159/000286342.

30. Al-Buhairi AR, Philips SJ, Llewellyn G, et al. Prediction of infarct topography using the Oxfordshire Community Stroke Project classification of stroke subtypes. *Journal of Stroke and Cerebrovascular Diseases* 1998; 7: 339–343. DOI: 10.1016/s1052-3057(98)80052-9.

31. E MG, WJ M, DM S, et al. Relationship between pattern of intracranial artery abnormalities on transcranial doppler and oxfordshire community stroke project clinical classification of ischemic stroke. *Stroke* 2000; 31: 714–719. DOI: 10.1161/01.STR.31.3.714.

32. Wardlaw JM, Dennis MS, Lindley RI, et al. The validity of a simple clinical classification of acute ischaemic stroke. *Journal of Neurology* 1996; 243: 274–279. DOI: 10.1007/BF00868526.

33. Jackson C and Sudlow C. Are lacunar strokes really different?. *Stroke* 2005; 36: 891–901. DOI: 10.1161/01.STR.0000157949.34986.30.

34. Landau WM and Nassief A. Editorial comment- time to burn an issue? *Clinical Neurology and Neurosurgery* 2017; 159: 93–106. DOI: 10.1016/j.clineuro.2017.05.019.

35. Turner M, Barber M, Barber M, et al. Agreement between routine electronic hospital discharge and Scottish Stroke Care Audit (SSCA) data in identifying stroke in the Scottish population. *BMC Health Services Research* 2015; 15: 583. DOI: 10.1186/s12913-015-1244-y.

36. Jackson C, Crossland L, Dennis M, et al. Assessing the impact of the requirement for explicit consent in a hospital-based stroke study. *Qjm* 2008; 101: 281–289. DOI: 10.1093/qjmed/hcm152.

37. Research SGS. *Demographic Change in Scotland*. Edinburg: Research SGS, 2010.

38. Gutierrez J and Esenwa C. Secondary stroke prevention: challenges and solutions. *Vascular Health and Risk Management* 2015; 11: 437–450. DOI: 10.2147/VHRM.S63791.

39. Hankey GJ. Secondary stroke prevention. *The Lancet Neurology* 2014; 13: 178–194. DOI: 10.1016/S1474-4422(13)70255-2.

40. AlAlshaikh S, Quinn T, Dunn W, et al. Predictive factors of non-adherence to secondary preventative medication after stroke or transient ischaemic attack: a systematic review and meta-analyses. *European Stroke Journal* 2016; 1: 65–75. DOI: 10.1177/2396987316647187.